CN117769555A - 喜树碱衍生物、其药物组合物及其应用 - Google Patents
喜树碱衍生物、其药物组合物及其应用 Download PDFInfo
- Publication number
- CN117769555A CN117769555A CN202280054490.6A CN202280054490A CN117769555A CN 117769555 A CN117769555 A CN 117769555A CN 202280054490 A CN202280054490 A CN 202280054490A CN 117769555 A CN117769555 A CN 117769555A
- Authority
- CN
- China
- Prior art keywords
- reaction
- compound
- added
- group
- atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110955364 | 2021-08-19 | ||
| CN2021109553645 | 2021-08-19 | ||
| CN2021115152473 | 2021-12-13 | ||
| CN202111515247 | 2021-12-13 | ||
| CN202210515797 | 2022-05-12 | ||
| CN2022105157973 | 2022-05-12 | ||
| PCT/CN2022/113499 WO2023020605A1 (zh) | 2021-08-19 | 2022-08-19 | 喜树碱衍生物、其药物组合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117769555A true CN117769555A (zh) | 2024-03-26 |
Family
ID=85239565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280054490.6A Pending CN117769555A (zh) | 2021-08-19 | 2022-08-19 | 喜树碱衍生物、其药物组合物及其应用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250270227A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4389752A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024532768A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240049583A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117769555A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022330892A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3228345A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023020605A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
| KR20250004952A (ko) * | 2022-03-17 | 2025-01-08 | 씨젠 인크. | 캄프토테신 접합체 |
| JP2025515988A (ja) * | 2022-05-13 | 2025-05-23 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | カンプトテシン化合物、その調製方法及びその使用 |
| IL322897A (en) * | 2023-02-23 | 2025-10-01 | Phrontline Biopharma Hangzhou Co Ltd | Camptothecin derivatives and conjugates, methods for their preparation and medical uses |
| WO2024210687A1 (ko) * | 2023-04-06 | 2024-10-10 | 주식회사 피노바이오 | 항암 내성 극복을 위한 신규 캄토테신 유도체 및 이를 포함하는 항체-약물 접합체 |
| CN120858098A (zh) * | 2023-05-04 | 2025-10-28 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物及其制备方法和应用 |
| CN120826405A (zh) * | 2023-05-04 | 2025-10-21 | 四川科伦博泰生物医药股份有限公司 | 具有靶向作用的偶联物及其制备方法和用途 |
| WO2025153001A1 (zh) * | 2024-01-17 | 2025-07-24 | 北京泰德制药股份有限公司 | 含有噻唑[5,4-b]吡啶结构的抗体偶联药物及其用途 |
| WO2026130566A1 (zh) * | 2024-12-20 | 2026-06-25 | 上海复宏汉霖生物技术股份有限公司 | 一种配体-药物偶联物及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0540099T3 (da) * | 1991-10-29 | 1996-06-17 | Glaxo Wellcome Inc | Vandopløselige camptothecinderivater |
| CN1036197C (zh) * | 1992-01-28 | 1997-10-22 | 格拉克索有限公司 | 水溶性喜树碱衍生物 |
| JPH1171280A (ja) * | 1997-06-26 | 1999-03-16 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| CN111936169A (zh) * | 2018-04-06 | 2020-11-13 | 西雅图遗传学公司 | 喜树碱肽缀合物 |
| TWI920652B (zh) * | 2018-06-07 | 2026-04-01 | 美商思進公司 | 喜樹鹼結合物 |
| RS64961B1 (sr) | 2019-04-26 | 2024-01-31 | Immunogen Inc | Derivati kamptotecina |
| AU2022216696A1 (en) * | 2021-02-05 | 2023-08-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor, and application thereof |
| CN120093941A (zh) * | 2021-02-09 | 2025-06-06 | 苏州宜联生物医药有限公司 | 生物活性物偶联物及其制备方法和用途 |
| KR20240031235A (ko) * | 2021-05-27 | 2024-03-07 | 자임워크스 비씨 인코포레이티드 | 캄프토테신 유사체, 접합체 및 사용 방법 |
| CN117940432B (zh) * | 2021-09-01 | 2025-12-23 | 上海弼领生物技术有限公司 | 一种喜树碱类化合物、其制备方法和用途 |
| KR20250004952A (ko) * | 2022-03-17 | 2025-01-08 | 씨젠 인크. | 캄프토테신 접합체 |
| WO2023217227A1 (zh) * | 2022-05-12 | 2023-11-16 | 先声再明医药有限公司 | 喜树碱类衍生物及配体-药物偶联物 |
| JP2025515988A (ja) * | 2022-05-13 | 2025-05-23 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | カンプトテシン化合物、その調製方法及びその使用 |
-
2022
- 2022-08-19 JP JP2024508407A patent/JP2024532768A/ja active Pending
- 2022-08-19 EP EP22857914.0A patent/EP4389752A4/en active Pending
- 2022-08-19 CA CA3228345A patent/CA3228345A1/en active Pending
- 2022-08-19 KR KR1020247009078A patent/KR20240049583A/ko active Pending
- 2022-08-19 AU AU2022330892A patent/AU2022330892A1/en active Pending
- 2022-08-19 US US18/684,477 patent/US20250270227A1/en active Pending
- 2022-08-19 WO PCT/CN2022/113499 patent/WO2023020605A1/zh not_active Ceased
- 2022-08-19 CN CN202280054490.6A patent/CN117769555A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4389752A1 (en) | 2024-06-26 |
| AU2022330892A1 (en) | 2024-03-21 |
| WO2023020605A1 (zh) | 2023-02-23 |
| KR20240049583A (ko) | 2024-04-16 |
| JP2024532768A (ja) | 2024-09-10 |
| EP4389752A4 (en) | 2025-08-20 |
| CA3228345A1 (en) | 2023-02-23 |
| US20250270227A1 (en) | 2025-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113631557B (zh) | Jak激酶抑制剂及其制备方法和在医药领域的应用 | |
| JP2024532768A (ja) | カンプトテシン誘導体、その薬物組成物およびその応用 | |
| JP2025532125A (ja) | 新規なテトラヘテロサイクル化合物 | |
| TW202521549A (zh) | 一種稠環化合物及在kras抑制劑方面的應用 | |
| CN112745335B (zh) | 一种三并杂环化合物及其用途 | |
| CN112300153B (zh) | 一种杂环化合物、药物组合物和用途 | |
| TW202523324A (zh) | 一種稠環化合物及應用 | |
| CN105461714B (zh) | 并环类pi3k抑制剂 | |
| CN101305010A (zh) | Raf抑制剂化合物及其用法 | |
| CN112851663B (zh) | 一种并杂环化合物及其用途 | |
| KR102866724B1 (ko) | 아자헤테로아릴 화합물 및 이의 용도 | |
| CA3161739A1 (en) | Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof | |
| CN115038707B (zh) | 氮杂卓类稠环化合物及其医药用途 | |
| JP2022000455A (ja) | フラバグリン誘導体 | |
| CN112707905A (zh) | 一种三并杂环化合物及其制备方法和用途 | |
| CN116867779A (zh) | 用于癌症治疗的KRas抑制剂 | |
| CN113286796A (zh) | 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途 | |
| JP2022554385A (ja) | Wdr5阻害剤及び調節剤 | |
| CN113387962A (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 | |
| CN113248497B (zh) | 用作fgfr4抑制剂的稠环衍生物 | |
| EP4378943A1 (en) | 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof | |
| CN114920738B (zh) | 用于癌症治疗的KRas抑制剂 | |
| CN115433207A (zh) | 作为egfr抑制剂的大环杂环类化合物及其应用 | |
| WO2025148870A1 (zh) | Ras抑制剂 | |
| JP7688954B2 (ja) | イミダゾピリダジン系誘導体、その製造方法、医薬組成物及び使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information |
Country or region after: China Address after: No. 20 Yaogu Yiheng Road, Xiuying District, Haikou City, Hainan Province, 570311 Applicant after: Hainan Xiansheng Zaiming Pharmaceutical Co.,Ltd. Address before: No. 20 Yaogu Yiheng Road, Xiuying District, Haikou City, Hainan Province, 570311 Applicant before: Xiansheng Zaiming Pharmaceutical Co.,Ltd. Country or region before: China |
|
| CB02 | Change of applicant information | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Country or region after: China Address after: No. 20 Yaogu Yiheng Road, Xiuying District, Haikou City, Hainan Province, 570311 Applicant after: Xiandeng Medical Co.,Ltd. Address before: No. 20 Yaogu Yiheng Road, Xiuying District, Haikou City, Hainan Province, 570311 Applicant before: Hainan Xiansheng Zaiming Pharmaceutical Co.,Ltd. Country or region before: China |
|
| CB02 | Change of applicant information |